文献速递心脑血管急症重症综合管理与镇静镇痛

非缺氧性癫痫持续状态成人院内死亡预测:状态癫痫严重程度评分(STESS)的回顾性外部验证与机器学习分析

Retrospective External Validation of the Status Epilepticus Severity Score (STESS) to Predict In-hospital Mortality in Adults with Nonhypoxic Status Epilepticus: A Machine Learning Analysis.
PubMed 文献 · Neurocrit Care · 2022-10-13
一句话结论在非缺氧性癫痫持续状态成人中,STESS预测院内死亡的AUROC为0.688,识别存活者准确(阴性预测值高),对死亡预测价值较低。

本研究在意大利摩德纳学术医院连续纳入2013至2021年629例非缺氧性癫痫持续状态成人(≥16岁),回顾性外部验证STESS对院内死亡的预测价值,并用决策树机器学习分析STESS预测因子。院内死亡率23.4%(147/629);死亡患者STESS中位数3.9(SD 1.6)高于存活者2.7(SD 1.5)(p<0.001)。STESS预测死亡的AUROC为0.688(95%CI 0.641-0.734),bootstrap重采样后仅轻微下降;决策树正确分类90%存活者和34%死亡者,总体错误风险23.1%。作者认为STESS是有价值的预后工具,识别存活者准确(阴性预测值高),对院内死亡预测价值较低。

要点

  • 629例非缺氧性癫痫持续状态成人中院内死亡率23.4%(147/629),死亡者STESS中位数3.9(SD 1.6)高于存活者2.7(SD 1.5)(p<0.001)。
  • 死亡患者中82.3%(121/147)STESS为3-6分,17.7%(26/147)为0-2分(p<0.001)。
  • STESS预测院内死亡的AUROC为0.688(95%CI 0.641-0.734),bootstrap重采样后仅轻微下降。
  • 决策树分析中最重要的预测因子为发作类型,其次为年龄和癫痫持续状态起病时意识水平。
  • 昏迷性非惊厥性癫痫持续状态和年龄≥65岁预测死亡风险更高,全面性惊厥性癫痫持续状态和年龄<65岁与较低死亡风险相关。

适用人群与场景

  • 2013至2021年意大利摩德纳学术医院连续收治的非缺氧性癫痫持续状态成人(年龄≥16岁)。

研究设计与关键结果

  • 回顾性外部验证研究,连续纳入629例非缺氧性癫痫持续状态成人(年龄≥16岁),院内死亡率23.4%(147/629)。
  • 死亡患者STESS中位数3.9(SD 1.6)高于存活者2.7(SD 1.5)(p<0.001);全队列STESS中位数2.9(SD 1.6)。
  • 死亡患者中82.3%(121/147)STESS为3-6分,17.7%(26/147)为0-2分(p<0.001)。
  • STESS预测院内死亡的AUROC为0.688(95%CI 0.641-0.734),bootstrap重采样后仅轻微下降。
  • 决策树分析中最重要的预测因子为发作类型,其次为年龄和癫痫持续状态起病时意识水平;昏迷性非惊厥性癫痫持续状态和年龄≥65岁预测死亡风险更高,全面性惊厥性癫痫持续状态和年龄<65岁与较低死亡风险相关。
  • 决策树分析使用STESS变量正确分类90%的存活者和34%的死亡者,总体错误风险23.1%。

证据类型、等级与局限

  • 证据类型:回顾性外部验证研究,采用机器学习(决策树)分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为STESS是有价值的预后工具,在识别出院时存活患者方面似乎尤其准确和有效(阴性预测值高),而对院内死亡的预测价值较低。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The objective of this study was to validate the value of the Status Epilepticus Severity Score (STESS) in the prediction of the risk of in-hospital mortality in patients with nonhypoxic status epilepticus (SE) using a machine learning analysis.

METHODS: We included consecutive patients with nonhypoxic SE (aged ≥ 16 years) admitted from 2013 to 2021 at the Modena Academic Hospital. A decision tree analysis was performed using in-hospital mortality as a dependent variable and the STESS predictors as input variables. We evaluated the accuracy of STESS in predicting in-hospital mortality using the area under the receiver operating characteristic curve (AUROC) with 95% confidence interval (CI).

RESULTS: Among 629 patients with SE, the in-hospital mortality rate was 23.4% (147 of 629). The median STESS in the entire cohort was 2.9 (SD 1.6); it was lower in surviving compared with deceased patients (2.7, SD 1.5 versus 3.9, SD 1.6; p < 0.001). Of deceased patients, 82.3% (121 of 147) had scores of 3-6, whereas 17.7% (26 of 147) had scores of 0-2 (p < 0.001). STESS was accurate in predicting mortality, with an AUROC of 0.688 (95% CI 0.641-0.734) only slightly reduced after bootstrap resampling. The most significant predictor was the seizure type, followed by age and level of consciousness at SE onset. Nonconvulsive SE in coma and age ≥ 65 years predicted a higher risk of mortality, whereas generalized convulsive SE and age < 65 years were associated with a lower risk of death. The decision tree analysis using STESS variables correctly classified 90% of survivors and 34% of nonsurvivors after the SE, with an overall risk of error of 23.1%.

CONCLUSIONS: This validation study using a machine learning system showed that STESS is a valuable prognostic tool. The score appears particularly accurate and effective in identifying patients who are alive at discharge (high negative predictive value), whereas it has a lower predictive value for in-hospital mortality.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Brigo F, Turcato G, Lattanzi S, et al. Retrospective External Validation of the Status Epilepticus Severity Score (STESS) to Predict In-hospital Mortality in Adults with Nonhypoxic Status Epilepticus: A Machine Learning Analysis. Neurocrit Care. 2022. PMID: 36229575. doi:10.1007/s12028-022-01610-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。